HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study

This article was originally published in The Rose Sheet

Executive Summary

Six workout and weight loss brands contained DMAA and three other stimulants, according to a study in the Journal Clinical Toxicology. Researchers concluded consumers must be informed of risk so they know to check labels for three substances that indicate the presence of the stimulants.


Related Content

Probiotic Safety Latest Target Of Supplement Regulation Critic Cohen
FDA Closes Another Business Smuggling Drugs From China As Dietary Ingredients
States' Scrutiny Of Supplement Industry Could Climb Following Mid-Terms
NSF ‘Certified For Sport’ Apps Cuts Through Unsafe Supplement Clutter
Five Shanghai Suspects Charged After FDA Undercover Work On Spiked Supplements
FDA List Of Supplement Formulation Taboos Adds Ephedra-Like Ingredient
FDA Warnings Mark Tip Of Iceberg For Stimulant-Spiked Supplements – Study
Military Report Slams DMAA While GNC Claims Victory
FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts